Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.

Trial Profile

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Venglustat (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms MOVES-PD
  • Sponsors Sanofi; Sanofi Genzyme
  • Most Recent Events

    • 01 Jun 2017 Planned End Date changed from 1 Dec 2021 to 7 Apr 2022.
    • 01 Jun 2017 Planned primary completion date changed from 7 Nov 2019 to 1 Mar 2021.
    • 13 Mar 2017 Time frame of primary end point has been changed from baseline to Week 52 to baseline to Week 8, and at Week 52.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top